secwatch.observer — SEC 8-K summary
======================================

Issuer:     Innoviva, Inc. (INVA)
CIK:        0001080014
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001104659-23-000897
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Innoviva appoints Dr. Sapna Srivastava to board, effective Jan 1, 2023
----------------------------------------------------------------------

- Dr. Sapna Srivastava appointed to Board as independent director, effective Jan 1, 2023.
- Srivastava brings experience as former CFO of Intellia Therapeutics and Abide Therapeutics, and 15 years as biotech analyst.
- Received initial RSU award of $125,000, prorated RSU of $56,250, and option for 2,500 shares.
- Annual cash retainer of $50,000 for board service.
- Bylaws amended to remove reference to SmithKline Beecham and update director nomination procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/0001104659-23-000897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/tm231444d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-000897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer